News

Katherine Poruk, MD, discusses upcoming surgical advances being made the field of pancreatic cancer.

Sotorasib produced an objective response rate of 9.7% in patients with colorectal cancer.

Topline results from the phase 2 NOVA-II trial showed clinical efficacy and an acceptable safety profile with OQL011.

In an interview with Targeted Oncology, Shaji Kumar, MD, discussed the current standard of care in multiple myeloma, along with the need for risk stratification in this patient population.

In an interview with Targeted Oncology, Mark Roschewski, MD, discussed precision medicine in diffuse large B-cell lymphoma and using acalabrutinib in a pre-chemotherapy window to better understand its potential benefit.

The study of the XPO1 inhibitor for solid tumors aims to accrue 48 patients.

IMX-110 may soon be granted fast track designation for the treatment of rhabdomyosarcoma children.

Fifty percent of patients in the first 2 cohorts of an early-phase study experienced stable disease on annamycin, and no dose-limiting toxicities were observed.

A new Zangmeister Cancer Center location has opened in Grove City, Ohio.

Theodore W. Laetsch, MD, discusses which trials were used for the retrospective study of the TRK inhibitor larotrectinib for the treatment of TRK-fusion cancers, including thyroid cancers.

A phase 3 trial of consibelimab aims to enroll 560 patients with non–small cell lung cancer, who will be randomized to receive either consibelimab with chemotherapy, or chemotherapy alone.

Lurbinectedin is being evaluated as treatment of patients with small cell lung cancer in a phase 3 trial.

Patients with high levels of amphiregulin appeared to be at a higher risk of early death from acute graft-versus-host-disease, signaling that it may be a predictive biomarker.

Although cytokine release syndrome can occur in patients treated with APVO436, the event can be managed with steroids without adversely affecting treatment.

Tycel Phillips, MD, a clinical associate professor of hematology and medical oncology at the University of Michigan Health, discusses the mechanism of action of glofitamab in patients with mantle cell lymphoma.

The FDA closed 2021 with 5 new treatment options for cancer and multiple designations that may bring new therapies to the armamentarium for oncologists in the future.

Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.

An application for FDA approval has been filed for teclistamab as a potential treatment for patients with relapsed or refractory multiple myeloma.

A novel natural killer cell therapy is now on the fast track to FDA approval and being assessed in a phase 1 clinical trial.

In the community setting, brexucabtagene autoleucel shows efficacy in patients with relapsed/refractory mantle cell lymphoma.

A phase 2 study is underway to determine the efficacy and safety of selinexor in patients with myelofibrosis.

Darren R. Feldman, MD, discusses the standard of care for the treatment of testicular cancer.

Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.

As part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, discussed unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation. He also explained how to approach the treatment of patients with challenging non-clear cell tumors.

HER2 mutations are a major clinical biomarker in breast cancer. However, overcoming drug resistance remains a key clinical obstacle.

In an interview with Targeted Oncology, Toni Choueiri, MD, discusses the impact the approval of adjuvant pembrolizumab has had on the RCC space.

Cristiane D. Bergerot, PhD, discussed factors contributing to financial toxicity in patients with RCC and how it impacts oncology care providers.